Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Hinge Health, Inc.HNGE · Entity 377 | President | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Hinge Health, Inc.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 666,078 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Tax withholding · Disposed 831 · Balance 666,078 F1: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Livongo Health, Inc.
Report date October 30, 2020 · Filed October 30, 2020
Section 16 reporting ended · disclosed 2020-10-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 1
1 source rowRow 1 · 2020-10-30 · Disposition to issuer · Disposed 73,294 · Balance 0 F1: Includes 21,537 restricted stock units ("RSUs"). F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F3: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F4: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2025-12-10 | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-30 · Disposition to issuer · Disposed 105,572 · Balance 0 F4: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F6: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F5: Shares subject to the option are fully vested and immediately exercisable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2026-02-17 | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-30 · Disposition to issuer · Disposed 50,000 · Balance 0 F4: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F6: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F5: Shares subject to the option are fully vested and immediately exercisable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.38 · Expires 2026-11-15 | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-30 · Disposition to issuer · Disposed 125,000 · Balance 0 F4: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F6: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F7: One-fourth of the shares subject to the option vested on November 16, 2017 and 1/48 of the shares vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2027-12-03 | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-30 · Disposition to issuer · Disposed 120,000 · Balance 0 F4: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F6: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F8: One-fourth of the shares subject to the option vested on December 4, 2018 and 1/48 of the shares vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2028-06-18 | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-30 · Disposition to issuer · Disposed 100,000 · Balance 0 F4: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F6: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F9: One-fourth of the shares subject to the option vested on June 19, 2019 and 1/48 of the shares vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 21,537 restricted stock units ("RSUs").
F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any).
F3: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions).
F4: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020.
F5: Shares subject to the option are fully vested and immediately exercisable.
F6: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions).
F7: One-fourth of the shares subject to the option vested on November 16, 2017 and 1/48 of the shares vest monthly thereafter.
F8: One-fourth of the shares subject to the option vested on December 4, 2018 and 1/48 of the shares vest monthly thereafter.
F9: One-fourth of the shares subject to the option vested on June 19, 2019 and 1/48 of the shares vest monthly thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2020 Filed Sep 5, 2020 01:14 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 12,803 | $124.51 | $1,594,101.53 |
DisclosureSEC source: 0001209191-20-049683 · doc4.xml · nonDerivative · entry 4 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,575 F1 · kind: On August 5, 2020, the Issuer entered into an Agreement and Plan of Merger with Teladoc Health, Inc. ("Teladoc") and Tempranillo Merger Sub, Inc., a wholly-owned subsidiary of Teladoc ("Merger Sub"), pursuant to which Merger Sub will merge with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Teladoc (the "Merger"). Pursuant to the terms of the Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019 (the "Trading Plan"), all sales pursuant to the Trading Plan were automatically suspended following the public announcement of the Merger without any action by the reporting person, and the Trading Plan was subsequently terminated. The number of shares sold and reported on this form is consistent with the number of shares that would have been sold by the reporting person pursuant to the Trading Plan had the Trading Plan not been suspended in connection with the Merger. F2 · kind: Following the sales reported on this form, the reporting person continues to hold over 85% of the shares of the Issuer's common stock and vested stock options held immediately prior to such sales. Read SEC document |
| September 04, 2020 Filed Sep 5, 2020 01:14 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 10,773 | $124.41 | $1,340,268.93 |
DisclosureSEC source: 0001209191-20-049683 · doc4.xml · nonDerivative · entry 3 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,378 F1 · kind: On August 5, 2020, the Issuer entered into an Agreement and Plan of Merger with Teladoc Health, Inc. ("Teladoc") and Tempranillo Merger Sub, Inc., a wholly-owned subsidiary of Teladoc ("Merger Sub"), pursuant to which Merger Sub will merge with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Teladoc (the "Merger"). Pursuant to the terms of the Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019 (the "Trading Plan"), all sales pursuant to the Trading Plan were automatically suspended following the public announcement of the Merger without any action by the reporting person, and the Trading Plan was subsequently terminated. The number of shares sold and reported on this form is consistent with the number of shares that would have been sold by the reporting person pursuant to the Trading Plan had the Trading Plan not been suspended in connection with the Merger. F2 · kind: Following the sales reported on this form, the reporting person continues to hold over 85% of the shares of the Issuer's common stock and vested stock options held immediately prior to such sales. Read SEC document |
| September 04, 2020 Filed Sep 5, 2020 01:14 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionCommon Stock | 19,428 | $0.80 | $15,542.40 |
DisclosureSEC source: 0001209191-20-049683 · doc4.xml · nonDerivative · entry 2 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2020 Filed Sep 5, 2020 01:14 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionCommon Stock | 5,429 | $0.36 | $1,954.44 |
DisclosureSEC source: 0001209191-20-049683 · doc4.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2020 Filed Aug 28, 2020 20:21 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 738 | $132.53 | $97,807.14 |
DisclosureSEC source: 0001209191-20-048626 · doc4.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,294 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:21 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,071 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001209191-20-041067 · doc4.xml · derivative · entry 6 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,429 Underlying: Common Stock · 7,071 shares Expires 2024-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F5 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:21 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 17,786 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001209191-20-041067 · doc4.xml · derivative · entry 5 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,786 shares Expires 2024-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F5 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:21 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 3,300 | $75.65 | $249,637.08 |
DisclosureSEC source: 0001209191-20-041067 · doc4.xml · nonDerivative · entry 4 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,032 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.365 to $76.08, inclusive. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:21 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 7,039 | $74.83 | $526,721.33 |
DisclosureSEC source: 0001209191-20-041067 · doc4.xml · nonDerivative · entry 3 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,332 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.34 to $75.31, inclusive. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:21 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 14,518 | $73.86 | $1,072,260.28 |
DisclosureSEC source: 0001209191-20-041067 · doc4.xml · nonDerivative · entry 2 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,371 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.34 to $74.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:21 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionCommon Stock | 24,857 | $0.36 | $8,948.52 |
DisclosureSEC source: 0001209191-20-041067 · doc4.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. Read SEC document |
| May 26, 2020 Filed May 28, 2020 22:04 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 346 | $55.00 | $19,030.00 |
DisclosureSEC source: 0001209191-20-032698 · doc4.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,032 F1 · shares: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:58 UTC | Livongo Health, Inc. LVGO · Entity 145566 | GrantCommon Stock | 13,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030241 · doc4.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,378 F1 · shares: The reported shares are represented by restricted stock units which vest in 16 equal quarterly installments beginning on August 25, 2020. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 20:50 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 24,857 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001209191-20-022624 · doc4.xml · derivative · entry 4 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,786 Underlying: Common Stock · 24,857 shares Expires 2024-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F4 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 20:50 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 11,200 | $27.21 | $304,783.36 |
DisclosureSEC source: 0001209191-20-022624 · doc4.xml · nonDerivative · entry 3 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,573 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.14 to $27.39, inclusive. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 20:50 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 13,657 | $26.93 | $367,785.74 |
DisclosureSEC source: 0001209191-20-022624 · doc4.xml · nonDerivative · entry 2 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,773 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.14 to $27.138, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 20:50 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionCommon Stock | 24,857 | $0.36 | $8,948.52 |
DisclosureSEC source: 0001209191-20-022624 · doc4.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 22:10 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 24,857 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001209191-20-017449 · doc4.xml · derivative · entry 5 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,643 Underlying: Common Stock · 24,857 shares Expires 2024-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F5 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 22:10 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 9,023 | $27.96 | $252,319.17 |
DisclosureSEC source: 0001209191-20-017449 · doc4.xml · nonDerivative · entry 4 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,573 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.89 to $28.04, inclusive. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 22:10 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 14,410 | $27.55 | $397,063.23 |
DisclosureSEC source: 0001209191-20-017449 · doc4.xml · nonDerivative · entry 3 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,596 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.89 to $27.87, inclusive. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 22:10 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 1,424 | $26.34 | $37,507.31 |
DisclosureSEC source: 0001209191-20-017449 · doc4.xml · nonDerivative · entry 2 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,006 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.72 to $26.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 22:10 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Exercise / conversionCommon Stock | 24,857 | $0.36 | $8,948.52 |
DisclosureSEC source: 0001209191-20-017449 · doc4.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:33 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 271 | $25.27 | $6,848.17 |
DisclosureSEC source: 0001209191-20-013027 · doc4.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,573 F1 · kind: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| December 02, 2019 Filed Jan 24, 2020 01:56 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 222 | $27.68 | $6,144.96 |
DisclosureSEC source: 0001209191-20-004770 · doc4.xml · nonDerivative · entry 2 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,844 F1 · kind: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| October 23, 2019 Filed Jan 24, 2020 01:56 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 234 | $21.32 | $4,988.88 |
DisclosureSEC source: 0001209191-20-004770 · doc4.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,066 F1 · kind: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 20:35 UTC | Livongo Health, Inc. LVGO · Entity 145566 | ConversionSeries A Convertible Preferred Stock · Derivative | 48,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-020585 · doc4.xml · derivative · entry 2 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 20:35 UTC | Livongo Health, Inc. LVGO · Entity 145566 | ConversionCommon Stock | 48,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-020585 · doc4.xml · nonDerivative · entry 1 Pursley James · CIK 0001783108 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.